- Home
- EVAX vs LGVN Comparison
EVAX vs LGVN Comparison
Compare EVAX & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- LGVN
- Stock Information
- Founded
- EVAX 2008
- LGVN 2014
- Country
- EVAX Denmark
- LGVN United States
- Employees
- EVAX N/A
- LGVN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- EVAX Health Care
- LGVN Health Care
- Exchange
- EVAX Nasdaq
- LGVN Nasdaq
- Market Cap
- EVAX 17.8M
- LGVN 16.6M
- IPO Year
- EVAX 2021
- LGVN 2021
- Fundamental
- Price
- EVAX $2.94
- LGVN $0.79
- Analyst Decision
- EVAX Strong Buy
- LGVN Strong Buy
- Analyst Count
- EVAX 2
- LGVN 2
- Target Price
- EVAX $10.00
- LGVN $6.50
- AVG Volume (30 Days)
- EVAX 88.6K
- LGVN 492.7K
- Earning Date
- EVAX 10-30-2025
- LGVN 11-11-2025
- Dividend Yield
- EVAX N/A
- LGVN N/A
- EPS Growth
- EVAX N/A
- LGVN N/A
- EPS
- EVAX N/A
- LGVN N/A
- Revenue
- EVAX $3,176,000.00
- LGVN $2,073,000.00
- Revenue This Year
- EVAX N/A
- LGVN N/A
- Revenue Next Year
- EVAX N/A
- LGVN $10.78
- P/E Ratio
- EVAX N/A
- LGVN N/A
- Revenue Growth
- EVAX 1042.45
- LGVN 68.67
- 52 Week Low
- EVAX $1.20
- LGVN $0.63
- 52 Week High
- EVAX $17.20
- LGVN $2.48
- Technical
- Relative Strength Index (RSI)
- EVAX 52.59
- LGVN 37.95
- Support Level
- EVAX $2.71
- LGVN $0.78
- Resistance Level
- EVAX $3.04
- LGVN $0.85
- Average True Range (ATR)
- EVAX 0.19
- LGVN 0.05
- MACD
- EVAX -0.02
- LGVN 0.02
- Stochastic Oscillator
- EVAX 57.53
- LGVN 46.30
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.